NO20055857L - Materialer og fremgangsmater til immunisering mot FIV-infeksjon - Google Patents

Materialer og fremgangsmater til immunisering mot FIV-infeksjon

Info

Publication number
NO20055857L
NO20055857L NO20055857A NO20055857A NO20055857L NO 20055857 L NO20055857 L NO 20055857L NO 20055857 A NO20055857 A NO 20055857A NO 20055857 A NO20055857 A NO 20055857A NO 20055857 L NO20055857 L NO 20055857L
Authority
NO
Norway
Prior art keywords
methods
fiv
materials
present
compositions
Prior art date
Application number
NO20055857A
Other languages
English (en)
Norwegian (no)
Inventor
Janet K Yamamoto
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of NO20055857L publication Critical patent/NO20055857L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20055857A 2003-05-12 2005-12-09 Materialer og fremgangsmater til immunisering mot FIV-infeksjon NO20055857L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47006603P 2003-05-12 2003-05-12
PCT/US2004/014928 WO2004100985A2 (en) 2003-05-12 2004-05-12 Materials and methods for immunizing against fiv infection

Publications (1)

Publication Number Publication Date
NO20055857L true NO20055857L (no) 2006-02-10

Family

ID=33452358

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055857A NO20055857L (no) 2003-05-12 2005-12-09 Materialer og fremgangsmater til immunisering mot FIV-infeksjon

Country Status (14)

Country Link
US (2) US20050031639A1 (pt)
EP (1) EP1622644A2 (pt)
JP (1) JP2006528244A (pt)
KR (1) KR20060032138A (pt)
CN (1) CN100387301C (pt)
AU (1) AU2004238367A1 (pt)
BR (1) BRPI0410422A (pt)
CA (1) CA2525641A1 (pt)
MX (1) MXPA05012270A (pt)
NO (1) NO20055857L (pt)
NZ (1) NZ543381A (pt)
RU (1) RU2005138501A (pt)
WO (1) WO2004100985A2 (pt)
ZA (1) ZA200508853B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410422A (pt) 2003-05-12 2006-05-30 Univ Florida materiais e processos para para imunização contra infecção por fiv
US7658927B2 (en) * 2003-05-12 2010-02-09 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection
DE602004021829D1 (de) 2003-09-11 2009-08-13 Idexx Lab Inc Verfahren zum nachweis des felinen immunschwächevirus
AU2005267607B8 (en) 2003-09-11 2009-07-16 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
AU2004304348B2 (en) 2003-12-18 2009-02-26 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
ATE504834T1 (de) 2004-02-19 2011-04-15 Idexx Lab Inc Verfahren und vorrichtung zum nachweis von katzen-immunschwächevirus
CA2576930C (en) 2004-06-30 2011-06-07 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus (fiv) comprising the use of peptides derived from the v3 region of the fiv env protein
JP4662988B2 (ja) * 2004-06-30 2011-03-30 アイデックス ラボラトリーズ インコーポレイテッド ネコ免疫不全ウイルスを検出するための方法および装置
US7291338B2 (en) 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
WO2011123781A1 (en) 2010-04-02 2011-10-06 Idexx Laboratories, Inc. Detection of feline immunodeficiency virus
WO2013040766A1 (zh) * 2011-09-21 2013-03-28 中国疾病预防控制中心性病艾滋病预防控制中心 可诱导针对hiv的广谱免疫应答的方法和疫苗
JP2013116869A (ja) * 2011-12-02 2013-06-13 Vaxxinova Kk 細胞内在ウイルスを主成分とする伝染性ファブリキウス嚢病生ワクチン
JP2018528974A (ja) * 2015-09-25 2018-10-04 フロリダ大学 リサーチファウンデーション インコーポレイティッド ヒトおよびネコにおけるワクチンのためのｈｉｖ、ｓｉｖおよびｆｉｖの交差反応性ｔ細胞エピトープ

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861720A (en) * 1986-07-03 1989-08-29 Regents Of The University Of California Oncornavirus vaccines and feline alpha-type interferon
CA1341439C (en) * 1987-08-26 2003-09-23 Niels C. Pedersen Feline t-lymphotropic lentivirus
US5118602A (en) * 1987-08-26 1992-06-02 The Regents Of The University Of California Feline T-lymphotropic lentivirus assay
US6107077A (en) * 1987-08-26 2000-08-22 Yamamoto; Janet K. Feline lymphoid cell lines capable of producing FIV for FIV diagnostics and vaccines
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991009869A1 (en) * 1990-01-05 1991-07-11 Medical Research Council Hiv-1 core protein fragments
AU647108B2 (en) * 1990-04-03 1994-03-17 Genentech Inc. Methods and compositions for vaccination against HIV
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
US5229364A (en) * 1991-03-15 1993-07-20 Francesca Chiodi Polypeptides derived from the human immunodeficiency virus endonuclease protein
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1993001278A1 (en) 1991-07-05 1993-01-21 The Regents Of The University Of California Feline lymphoid cell lines capable of producing fiv
WO1994020622A1 (en) 1993-03-11 1994-09-15 Akzo Nobel N.V. Polypeptide fragment capable of inducing neutralising antibodies against feline immuno-deficiency virus
WO1994028929A1 (en) 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides
IT1276509B1 (it) 1995-03-31 1997-10-31 Istituto Superiore Della Sanit Vaccino per la profilassiimmunitaria dell'infezione da virus della immunodeficienza felina del gatto domestico.
EP0759468A1 (en) * 1995-08-10 1997-02-26 Laboratoires Virbac Feline interleukin-4
US6254872B1 (en) * 1995-08-25 2001-07-03 University Of Florida Multi-subtype FIV vaccines
DK0848615T3 (da) 1995-08-25 2005-10-03 Univ Florida Muilti-undertyoe-FIV-vacciner
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
EP1045921A2 (en) * 1998-01-16 2000-10-25 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
US6503753B1 (en) * 1998-02-13 2003-01-07 Adan Rios Method for the development of an HIV vaccine
US6500623B1 (en) * 1998-05-12 2002-12-31 Genecure Llp Replication defective HIV vaccine
AU2221600A (en) * 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1074625A3 (en) * 1999-06-14 2002-01-02 Pfizer Products Inc. DNA vaccine against feline immunodeficiency virus
KR100354562B1 (ko) * 1999-12-06 2002-09-30 주식회사 제넥신 원숭이에서 ＳＩＶｍａｃ２３９의 감염에 대한 방어를유도하는 ＡＩＤＳ ＤＮＡ 백신
CA2414926A1 (en) * 2000-07-07 2002-01-17 Corixa Corporation Microspheres and adjuvants for dna vaccine delivery
US20030091987A1 (en) * 2001-02-22 2003-05-15 Yamamoto Janet K. Materials and methods for detecting, preventing, and treating retroviral infection
BRPI0410422A (pt) 2003-05-12 2006-05-30 Univ Florida materiais e processos para para imunização contra infecção por fiv
US7658927B2 (en) * 2003-05-12 2010-02-09 University Of Florida Research Foundation, Inc. Materials and methods for immunizing against FIV infection

Also Published As

Publication number Publication date
US20050031639A1 (en) 2005-02-10
AU2004238367A1 (en) 2004-11-25
US20100111899A1 (en) 2010-05-06
NZ543381A (en) 2008-04-30
CN100387301C (zh) 2008-05-14
EP1622644A2 (en) 2006-02-08
AU2004238367A2 (en) 2004-11-25
MXPA05012270A (es) 2006-02-10
CN1812810A (zh) 2006-08-02
RU2005138501A (ru) 2006-06-27
BRPI0410422A (pt) 2006-05-30
US8703145B2 (en) 2014-04-22
KR20060032138A (ko) 2006-04-14
WO2004100985A2 (en) 2004-11-25
CA2525641A1 (en) 2004-11-25
ZA200508853B (en) 2007-02-28
WO2004100985A3 (en) 2005-03-24
JP2006528244A (ja) 2006-12-14

Similar Documents

Publication Publication Date Title
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
MXPA05012270A (es) Materiales y metodos para inmunizar en contra de la infeccion por virus de inmunodeficiencia de felino.
DK1147117T3 (da) Immunologiske adjuvansforbindelser
WO2007024941A3 (en) Polyvalent vaccine
NO992369D0 (no) Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus
WO2002032943A3 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
DK0848615T3 (da) Muilti-undertyoe-FIV-vacciner
DE60336978D1 (de) Synthetische Peptid-HIV-Vakzine: das CBD-Epitop als effizientes Immunogen zur Induktion HIV-neutralisierender Antikörper
DE60115051D1 (de) Immunologische adjuvans verbindungen
ATE294857T1 (de) Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
WO2005027844A3 (en) Dna vaccine compositions and methods of use
FI1855720T4 (fi) Muunnellun rokkoviruksen käyttö immuniteetin nopeaksi indusoimiseksi rokkovirusta tai muita infektoivia aineita vastaan
WO2007079457A3 (en) Materials and methods for immunizing against fiv infection
EA201401044A1 (ru) Модифицированный вирус болезни марека и вакцины на его основе
WO2006091455A3 (en) Molecular scaffolds for hiv-1 immunogens
NO20060395L (no) Antigenholdig dyrevaksine
Camus Development and characterization of Lassa virus vaccines and mouse model
WO2004062567A3 (en) Arterivirus marker vaccine
RU2006131153A (ru) Способ иммунизации против вирусных инфекций человека и животных с использованием неиммуногенных и слабоиммуногенных вирусных белков и усиления трансмембранного переноса антител внутрь клеток

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application